TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01517932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery
Study: NCT01710891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CMAC videolaryngoscope
Description: patients are intubated using the CMAC video laryngoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: Patients undergo their first intubation attempt using direct laryngoscopy with a C-MAC device with the video display covered with a hood.
Study: NCT03671941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D578
Description: D578 Tab.1T single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-357
Description: CKD-357 Tab.1T single oral administration under fasting condition
Study: NCT02356445

Intervention type: OTHER
Intervention: Cytotoxic drug
Description: Observe patients versus treatment type
Study: NCT03242486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: toric intraocular lens
Study: NCT04792736

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood lactate level
Description: Blood lactate level measured at admission H0, every 6 hours during the first 24 h and at H48

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood lactate level
Description: Blood lactate level measured at admission H0, every 6 hours during the first 24 h and at H48
Study: NCT02761226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platform Matched Design (Group A)
Description: 10 patients with missing upper posterior teeth will receive dental implant with platform matched design (the patients will receive implant 4.2mm with same abutment diameter 4.2mm)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platform Switching Design (Group B)
Description: 10 patients with missing upper posterior teeth will receive dental implant with platform switching design(the patients will receive implant 4.2mm with smaller abutment diameter 3.5 mm
Study: NCT00963963

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Futures parent education
Description: Multi-year audio CD parent education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Futures parent education
Description: Multi-year audio CD parent education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Futures parent education
Description: Multi-year audio CD parent education
Study: NCT04759235

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Anatomical (T2W) and functional MRI (DWI) at a 3.0T Siemens or Philips scanner Three MRI scan series (before, during, after nCRT) Measurements: change in apparent diffusion coefficient (ADC)

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT)
Description: PET-CT scan at diagnosis and 4-6 weeks after nCRT before operation Measurements: change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value)，MTV（Metabolic tumor volume）

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine metabolic biomarker
Description: Blood and urine specimens are collected before radiotherapy, the third week of radiotherapy, and at the end of radiotherapy.
Study: NCT03549975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 100 unit/Vial (Product)
Description: Botulinum toxin type A injection followed by functional electrical stimulation
Study: NCT04507022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate
Description: 2mg three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate
Description: 2mg three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 100 mg daily intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 100 mg daily intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: 2.5 mg twice daily for 5 days
Study: NCT02136966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MNP + IYCN counseling + cooking demonstrations
Description: Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
Study: NCT03596905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Description: Taken orally daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Description: Taken orally daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Description: Taken orally daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Description: Taken orally daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Taken orally daily for 4 weeks
Study: NCT02237326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visual Inspection with Acetic Acid
Description: Visual Inspection with Acetic Acid is the application of acetic acid to a cervix, followed by examination with a light source. It is not a new drug or device, and has been used in resource-limited settings for several decades. The purpose of this trial is to compare the two screening techniques, which had not been done previously.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visual Inspection with Lugol's Iodine
Description: Visual Inspection with Lugol's Iodine is the application of lugol's iodine to a woman's cervix, followed by examination with a light source with the goal of detecting precancerous lesions. Like Visual Inspection with Acetic Acid, it is not a new drug or device.
Study: NCT05439044

Intervention type: OTHER
Intervention: Data collection
Description: Anti SARS-CoV-2 Monoclonal Antibodies: casirivimab-imdevimab (Ronapreve) OR bamlanivimab-etesevimab OR tixagevimab-cilgavimab (Evusheld) OR regdanvimab OR sotrovimab (Xevudy) OR adintrevimab
Study: NCT02785185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-122 Vehicle Lotion
Description: Vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-122 Vehicle Cream
Description: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-122 Lotion
Description: Lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultravate Cream
Description: Cream
Study: NCT03955835

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.
Description: Self-expandable Credo® stent together with NeuroSpeed® PTA balloon catheter. Credo® and NeuroSpeed® are already CE approved products, for which within ACUTE an additional new indication shall be examined.
Study: NCT01373463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed by vein every 21 days for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin by vein Every 21 days for 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment 5 days a week for 5-6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed by vein every 21 days for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin by vein every 21 days for 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment 5 days a week for 5-6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lobectomy
Description: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lobectomy
Description: Surgery to remove a portion of the lung where the tumor is located.
Study: NCT00833040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual sufentanil NanoTabs™ and placebo NanoTabs™
Description: During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
Study: NCT04458155

Intervention type: DEVICE
Intervention: Siemens® Point-of-care high sensitive troponin I analyzer
Description: Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Siemens® device.
Study: NCT00420485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gimatecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gimatecan
Study: NCT01067378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-led debriefing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expert instructor debriefing
Study: NCT02495701

Intervention type: PROCEDURE
Intervention: Hip arthroscopic surgery
Description: Hip arthroscopic surgery
Study: NCT04085419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab 60 MG/ML Prefilled Syringe [Prolia]
Description: denosumab 60 mg subcutaneously every 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: zoledronic acid 5 mg intravenously once a year
Study: NCT00666666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101
Description: AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LHRH agent
Description: An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
Study: NCT03885635

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarch repair
Description: Current standard of surgical repair consisting of ascending aortic replacement with open distal anastomosis at level of proximal arch under a period of hypothermic circulatory arrest . No surgical or endovascular intervention is carried out in the mid arch or descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended arch repair
Description: Surgical replacement of the ascending aorta along with intervention on the arch and descending aorta. Techniques for distal aspect of extended arch technique include but are not limited to total arch replacement along with TEVAR, Frozen Elephant Trunk procedure or surgical proximal arch replacement with bare metal stents in arch and descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
Study: NCT01758809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-emptive bupivacaine wound infiltration
Description: Pre-emptive bupivacaine wound infiltration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intravenous patient controlled analgesia
Description: postoperative pain control with intravenous patient controlled analgesia
Study: NCT03935958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients will receive curcumin 2000 mg a day, for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
Study: NCT01046981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumescent Antibiotic Delivery of cefazolin with or without metronidazole
Description: TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Antibiotic Delivery
Description: Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
Study: NCT01161186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel, gemcitabine, capecitabine
Description: {nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
Study: NCT03929172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVLP-HPV
Description: 20μg/injection formulated in a ready to use solution containing 100mM sodium citrate, 2.5 mM MgCl2, 0.001% pluronic F-68, pH 6.0 for i.m. injection as 0.5 mL per injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL 100 mM Sodium Citrate, 2.5 mM MgCl2, 0.001% Pluronic F-68, pH 6 for i.m. injection as 0.5 mL per injection.
Study: NCT04569877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim nebuliser solution
Description: 300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nebuliser solution
Description: Placebo nebulised seven times within 7 days via rapid nebuliser system
Study: NCT03624673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic robot-assisted simple enucleation
Description: Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard robot-assisted partial nephrectomy
Description: Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
Study: NCT01102088

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions.
Study: NCT02718521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate
Description: Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
Study: NCT01480219

Intervention type: DRUG
Intervention: voriconazole (Vfend)
Description: Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.

Intervention type: OTHER
Intervention: no voriconazole (Vfend)
Description: Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
Study: NCT02718521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate
Description: Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque
Description: All study participants received intra-arterial (320 mg I/ml; GE Healthcare)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride ﬂuid administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride ﬂuid administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate
Study: NCT00917930

Intervention type: BEHAVIORAL
Intervention: physical training
Description: intensive cardiac rehabilitation program
Study: NCT02316028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: administration of decitabine by hepatic arterial infusion~* Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~* Proposed dose levels:~  1. 10 mg/m2 per course~ 2. 15 mg/m2 per course~ 3. 20 mg/m2 per course
Study: NCT04636281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active and passive static stretching exercises
Description: Different group of muscles will be stretched one by one, tricep brachii, bicep brachii, wrist exentsor etc

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active and passive static stretching exercises
Description: Different group of muscles will be stretched one by one, tricep brachii, bicep brachii, wrist exentsor etc
Study: NCT03546985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: episil®
Description: Firmly press the pump and apply the stream of liquid to the oral cavity 3 times (a total volume of 0.45 mL approximately). Distribute to affected areas in the mouth, for example by using the tongue. Wait for 5 minutes for the protective film to form.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kang Su
Description: Gently pour 5 mL of rinse into the mouth, keep the rinse staying in the oral cavity for at least 1 minute, and spilt out the liquid.
Study: NCT04061122

Intervention type: DIAGNOSTIC_TEST
Intervention: airway epithelial smear test
Description: all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture

Intervention type: DIAGNOSTIC_TEST
Intervention: airway epithelial smear test
Description: all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture

Intervention type: DIAGNOSTIC_TEST
Intervention: airway epithelial smear test
Description: all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture

Intervention type: DIAGNOSTIC_TEST
Intervention: airway epithelial smear test
Description: all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture
Study: NCT00530413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: Phenobarbital will be given based on weight range

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study: NCT01062750

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: adipose tissue derived stromal cells dosage
Description: single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
Study: NCT00503750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre operativeTrastuzumab
Description: Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.~As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-007 (Abraxane)
Description: ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
Study: NCT02123134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study: NCT03827408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam group (MDZ)
Description: IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland
Study: NCT02518321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology-Assisted Toileting

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology-Assisted Toileting